Mirum Pharmaceuticals/$MIRM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Mirum Pharmaceuticals

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Ticker

$MIRM
Sector
Primary listing

Employees

349

MIRM Metrics

BasicAdvanced
$3.6B
-
-$1.20
0.95
-

What the Analysts think about MIRM

Analyst ratings (Buy, Hold, Sell) for Mirum Pharmaceuticals stock.

Bulls say / Bears say

In the second quarter of 2025, Mirum's total revenue jumped 64% year-over-year to reach $127.8 million, surpassing analyst expectations and prompting the company to increase its full-year 2025 revenue forecast to between $490 million and $510 million (Zacks)
Livmarli net product sales totaled $88.2 million in Q2 2025, representing an 87% year-over-year increase, fueled by robust demand in both the U.S. and international markets and highlighting Mirum’s leadership in cholestatic pruritus therapies (Zacks)
As of June 30, 2025, Mirum’s cash, cash equivalents, and investments increased to $321.7 million from $298.6 million as of March 31, strengthening its financial position as it continues to invest in research and development (Zacks)
Despite strong revenue growth, Mirum remained unprofitable in Q2 2025 with a loss per share of $0.12, signaling continued dependence on outside funding to support operations (Zacks)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

MIRM Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MIRM Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MIRM

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs